BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

Published:2013-01 Issue:1 Volume:25 Page:106-112
ISSN:0898-6568
Container-title:Cellular Signalling
language:en
Short-container-title:Cellular Signalling

Author:

Rushworth Stuart A.,Bowles Kristian M.,Barrera Lawrence N.,Murray Megan Y.,Zaitseva Lyubov,MacEwan David J.

Funder

Association for International Cancer Research

National Institutes for Health Research (Flexibility and Sustainability Funding)

The Big C

Leukaemia and Lymphoma Research

Publisher

Elsevier BV

Subject

Cell Biology

Reference27 articles.

1. author index

2. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

3. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

4. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation

5. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation;Journal of Hematology & Oncology;2024-09-02

2. NF-kB affects migration of vascular smooth muscle cells after treatment with heparin and ibrutinib;Biochemistry and Biophysics Reports;2024-07

3. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial;Nature Communications;2024-03-30

4. Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma;Haematologica;2023-12-21

5. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway;Anti-Cancer Agents in Medicinal Chemistry;2023-07-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3